1. Odongpiny ELA, Otaalo B, Musaazi J, Nalugga EA, et al.
   Risks and possible implications of weight gain after switch to dolutegravir- in a large Ugandan cohort of people living with HIV.
   AIDS 2026.
   


2. Lake JE, Kitch DW, Kantor A, Alonso C, et al.
   Semaglutide improves markers of cardiovascular risk in people with HIV.
   AIDS 2026.
   


3. Mafuta C, Grabar S, Lievre L, Tran L, et al.
   Factors associated with loss to follow-up among people living with HIV in France.
   AIDS 2026.
   


4. Stephen ZR, Perazzolo S, Duan L, Eguchi M, et al.
   A novel all-in-one injectable composed of tenofovir alafenamide-dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks.
   AIDS 2026.
   


5. Foster C, Blenkinsop A, Henderson M, Lyall H, et al.
   Risk factors associated with adverse metabolic health in youth with perinatally acquired HIV living in the United Kingdom.
   AIDS 2026.
   


6. Zhao D, Sun L, Cen P, He Y, et al.
   Renal outcomes with dolutegravir plus lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in ART-naive adults with HIV.
   AIDS 2026.
   


7. Augello M, Mingione A, Borghi L, Corona A, et al.
   Astrocyte/monocyte activation and inflammation are associated with asymptomatic neurocognitive impairment in people with HIV on suppressive antiretroviral therapy.
   AIDS 2026.
   


8. Camard M, Placais L, Bitu M, Mouanga C, et al.
   Modulation of TLR-driven monocyte activation by JAK-STAT inhibitors in people with HIV.
   AIDS 2026.
   


9. Hockney S, Mueller D, Phillbrick A, Berlet J, et al.
   Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir-Rilpivirine.
   AIDS Res Hum Retroviruses 2026.
   


10. Khalili M, Haghdoost F, Liaghatdar A, Torabiardakani K, et al.
    Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine : A Systematic Review of Randomized Controlled Trials.
    Ann Intern Med 2026.
    


11. Foncillas A, Ambrosioni J, de la Mora L, Mallolas J, et al.
    Atypical HBV Serological Patterns After Switching to CAB/RPV: Interpretation Within Current Definitions.
    Clin Infect Dis 2026.
    


12. Adachi E, Yotsuyanagi H.
    Anti-HBs Seroconversion Following Withdrawal of Anti-HBV-Active Agents: An Underrecognized Form of HBV Reactivation?
    Clin Infect Dis 2026.
    


13. Reddy K, Kuhn L, Barnabas S, Molechan C, et al.
    Proviral HIV-1 DNA Below Detection in Early Treated Adolescents After Prior Treatment Interruption.
    J Acquir Immune Defic Syndr 2026.
    


14. Kizito S, Ssewamala FM, Nabayinda J, Nabunya P, et al.
    Comparing Self-Reports, Pill Counts, and Electronic Devices in Assessing ART Adherence and its Association with Viral Suppression in Adolescents Living with HIV.
    J Acquir Immune Defic Syndr 2026.
    


15. Hay Wong JM, Lee T, Av-Gay G, Azampanah A, et al.
    Developing a Preterm Birth Prediction Model in Pregnant People with HIV using a Population-Based Cohort.
    J Acquir Immune Defic Syndr 2026.
    


16. Kuniholm MH, Murenzi G, Samala N, Yunihastuti E, et al.
    Hepatitis B and C Prevention, Screening and Diagnostic Services at HIV Treatment Sites: International epidemiology Databases to Evaluate AIDS.
    J Acquir Immune Defic Syndr 2026.
    


17. Gay CL, Xu Y, Weideman AMK, Shaw FR, et al.
    MVA.tHIVconsvX vaccination-evoked T cell expansion inversely associates with age in people with HIV-1 on antiretroviral therapy.
    J Clin Invest 2026.
    


18. Nideffer J, Bach F, Strubbe S, Lopez L, et al.
    CXCR6+CD127- Tr1 cells balance immunity and persistence in Plasmodium falciparum infection.
    J Clin Invest 2026.
    


19. Pitchenik AE.
    A missed early signal of the HIV-tuberculosis syndemic in a 1982 MMWR report.
    J Infect Dis 2026.
    


20. Prodanuk M, Boillat-Blanco N, D'Acremont V, Fung A, et al.
    Host plasma protein biomarkers for tuberculosis disease screening in febrile adults in Tanzania.
    J Infect Dis 2026.
    


21. Mchantaf G, Maia X, Andriantsoanirina V, Dehan O, et al.
    Comparative Evaluation of the New HIV VIDAS(R) DUO AG/AB Assay With DUO Ultra on Well Characterized Participants From the HIV-1 Acute Infection French ANRS PRIMO Cohort.
    J Med Virol 2026;98:e70953.
    


22. Nikolopoulos N, Modis Y.
    Crystal structure of HERV-K envelope glycoprotein surface subunit.
    J Virol 2026.
    


23. Xie Q, Wang Q, Noettger S, Gosalbez G, et al.
    Replication-competent SIVcpz CRISPR screen identifies barriers to successful cross-species transmission.
    J Virol 2026.
    


24. Suomalainen M, Haenseler W, Kolibius J, Pluckthun A, et al.
    Transcriptional transactivation turns human iPSC-derived macrophages into an adenovirus-producing cell state.
    J Virol 2026.
    


25. Jalil EM, Veloso VG, Grinsztejn B.
    Brazilian elimination of mother-to-child HIV transmission: lessons for large-scale global health systems.
    Nat Med 2026.
    


26. Skelly AN, Gristick HB, Li H, Gavor E, et al.
    Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.
    Science 2026.
    

Display articles in

• Abstract format